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Abstract
Background: The heparin-binding plasma protein histidine-rich glycoprotein (HRG; alternatively, HRGP/HPRG) can suppress
tumor angiogenesis and growth in vitro and in vivo. Mice lacking the HRG gene are viable and fertile, but have an enhanced
coagulation resulting in decreased bleeding times. In addition, the angiogenic switch is significantly enhanced in HRG-
deficient mice.
Methodology/Principal Findings: To address whether HRG deficiency affects tumor development, we have crossed HRG
knockout mice with the RIP1-Tag2 mouse, a well established orthotopic model of multistage carcinogenesis. RIP1-Tag2
HRG
2/2 mice display significantly larger tumor volume compared to their RIP1-Tag2 HRG
+/+ littermates, supporting a role
for HRG as an endogenous regulator of tumor growth. In the present study we also demonstrate that platelet activation is
increased in mice lacking HRG. To address whether this elevated platelet activation contributes to the increased
pathological angiogenesis in HRG-deficient mice, they were rendered thrombocytopenic before the onset of the angiogenic
switch by injection of the anti-platelet antibody GP1ba. Interestingly, this treatment suppressed the increase in angiogenic
neoplasias seen in HRG knockout mice. However, if GP1ba treatment was initiated at a later stage, after the onset of the
angiogenic switch, no suppression of tumor growth was detected in HRG-deficient mice.
Conclusions: Our data show that increased platelet activation mediates the accelerated angiogenic switch in HRG-deficient
mice. Moreover, we conclude that platelets play a crucial role in the early stages of tumor development but are of less
significance for tumor growth once angiogenesis has been initiated.
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Introduction
Histidine-rich glycoprotein (HRG; alternatively, HRGP/
HPRG) has been identified as an angiogenesis inhibitor in vitro
and in vivo by us and others [1,2,3]. HRG is a 75 kDa single chain
heparin-binding plasma protein produced by the liver [4].
Structurally, HRG consists of three distinct domains; an amino-
terminal part with two cystatin (cysteine proteinase inhibitor)-like
domains, which classifies HRG as a member of the cystatin
superfamily together with e.g. kininogen and fetuin, a central
histidine/proline-rich (His/Pro-rich) domain organized in tandem
repeats of a consensus GHHPH motif, and a carboxy-terminal
domain. Multiple binding partners for HRG have been reported,
such as heparin/heparan sulfate, divalent cations, components in
the coagulation-fibrinolysis system; plasminogen and fibrinogen, as
well as components in the immune system such as T lymphocytes,
monocytes/macrophages and immunoglobulins [4]. Monocytes
were previously believed to express HRG, since HRG binds to the
cell surface of monocytes, but more recent data demonstrate that
RNA is found only in the liver [5]. In addition, HRG has been
reported to be present within platelets and megakaryocytes [6].
Mice lacking the HRG gene are viable and fertile, but have an
enhanced coagulation resulting in decreased bleeding times [7].
HRG thereby exemplifies one of several molecules regulating both
angiogenesis and hemostasis [8].
Platelets are anuclear cellular fragments derived from mega-
karyocytes in the bone marrow and play a crucial role in
regulating blood hemostasis. At sites of blood vessel injury,
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endothelium to prevent hemorrhage. Besides their role in
hemostasis, platelets contribute to non-hemostatic processes such
as immunity, tumor metastasis and angiogenesis [9,10,11].
Platelets contain a large number of both pro- and antiangiogenic
factors and regulation of angiogenesis by platelets was suggested as
early as 1968 [12]. Examples of positive regulators of angiogenesis
found in platelets are VEGF-A, VEGF-C, platelet-derived growth
factor (PDGF) and fibroblast growth factor-2 (FGF-2), while
negative regulators include thrombospondin, platelet factor-4 (PF-
4) and plasminogen activator inhibitor type-1 (PAI-1) [8,13].
Despite their content of both positive and negative regulators of
blood vessel formation, platelets have in several different
experimental settings been shown to stimulate angiogenesis
[11,14,15,16,17]. It is well known that cancer patients have an
increased turnover of platelets and increased risk of thrombotic
occlusion, as a result of increased platelet activation. Both
increased coagulation and platelet activation have been demon-
strated to stimulate tumor angiogenesis, as well as metastasis, and
can therefore contribute to disease progression [11,18].
In the present study we address how lack of HRG affects tumor
growth. For this purpose we have crossed HRG-deficient mice with
the orthotopic RIP1-Tag2 mouse model of insulinoma [19]. These
mice carry the SV40 T-antigens under the control of the insulin
promoter, which is expressed in the islets of Langerhans in the
pancreas. The Rip1-Tag2 is an orthotopic model of multistage
carcinogenesis, believed to better reflect the stepwise process of tumor
development via distinctive stages, than conventional subcutaneous
models with injected tumor cells. One of these stages represents the
‘‘angiogenic switch’’. Moreover, we investigate whether the deregu-
lated hemostasis in HRG-deficient mice contribute to the elevated
angiogenic switch, previously reported in these mice.
Materials and Methods
Antibodies
The following primary antibodies were used in this study: anti-
Ki67 (Dakocytomation/ M7249), anti-cleaved caspase-3 (Cell
Signalling/9661), anti-CD31 (BD/557355), anti-CD41 (BD/
553847) and anti- GP1ba (Emfret/R300). The following direct-
conjugated antibodies were used for flow cytometry: PE-
conjugated anti-mouse GPIIb/IIIa (JON/A/M023-2/Emfret),
PE-conjugated anti-P-selectin (Emfret/M130-2) and FITC-conju-
gated anti-GPIX (Emfret/M051-0). Control antibodies for flow
cytometric analysis were: PE-conjugated rat IgG (Emfret/P190-2),
FITC-conjugated rat IgG (Emfret/P190-1), rabbit IgG (Cedar-
lane/CLRB00) and FITC-conjugated rat IgM (555583/BD). The
following secondary antibodies were used: anti-rat Alexa488
(Molecular Probes/A21208), anti-rabbit (BA-1000/Vector Labo-
ratories), anti-mouse (BA-9200/Vector Laboratories) and anti-rat
(BA-9400/Vector Laboratories).
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the Uppsala
University board of animal experimentation (C279/7) and thus
performed according to the United Kingdom Coordinating
Committee on Cancer Research (UKCCCR) guidelines for the
welfare of animals in experimental neoplasia [20].
RIP1-Tag2 HRG
+/+ and RIP1-Tag2 HRG
2/2 mice
All mouse strains were on a pure C57BL/6 genetic background.
HRG deficient female mice were mated with RIP1-Tag2 positive
(RT2) males to produce founder mice for breeding of RT2/
HRG
2/2 and RT2/HRG
+/+ littermates. From 10 weeks of age,
all RIP1-Tag2 positive mice received drinking water supplied with
5% sucrose to relieve hypoglycemia induced by the insulin-
secreting tumors. DNA extracted from tail biopsies was used as the
template for genotyping by PCR. The following primers were
used: Forward HRG primer 59-CCTGGGGTCAAAGTGAA-
CATGC-39; reverse HRG wild-type primer 59-CGCTCTGT-
CCAAGTGGGCGTCA-39; reverse knockout HRG primer
(located in neomycin cassette) 59-TTGTGTAGCGCAAGTGC-
CAGCG-39; forward Tag2 primer 59-GGACAACCACAACTA-
GAATGCAG-39; reverse Tag2 primer 59-CAGAGCAGA-
ATTGTGGAGTGG-39.
Dissection and quantification of angiogenic islets and
tumors
Twelve or 15 weeks old RT2/HRG
+/+ or RT2/HRG
2/2 mice
were anesthetized by intraperitoneal injection of 2% avertin.
Heart perfusion was done with 10 ml of phosphate buffered saline
(PBS) (pH 7.4) followed by 10 ml of 2% paraformaldehyde (PFA)
in PBS (pH 7.4). Pancreases were removed from the abdominal
cavity and tumors and angiogenic islets were dissected away from
exocrine pancreas under a stereo dissection microscope at 610
magnification. Tumors and angiogenic islets (defined as blood
containing hyperplastic islet with a diameter of ,1 mm) were
measured and counted. Tumor volumes were calculated by the
formula ((p/6)6width
26length). Tumors and angiogenic islets
were stored in a 30% sucrose in PBS solution over night at 4uC.
The material was frozen in Tissue-TekH O.C.T. and stored at
270uC until further processing.
Immunohistochemistry
Frozen sections of mouse tissue were fixed in ice-cold methanol,
washed in PBS, incubated with 1% H2O2 to quench endogenous
peroxidases and blocked in 3% bovine serum albumin (BSA)+20%
horse serum in PBS for 30 min. To reduce background signal
from endogenous biotin in the pancreas, an avidin/biotin blocking
kit (SP-2001/Vector Laboratories) was applied before addition of
antibodies. Sections were incubated with primary antibody for
2 hours at room temperature or at 4uC over night. Primary
antibodies were diluted in blocking buffer as follows: CD31 1:500,
cleaved caspase-3 1:200, Ki67 1:100 and CD41 1:300. For
enzymatic detection, sections were incubated with 1% H2O2 prior
to blocking. In order to detect primary antibody binding sites,
sections were incubated with biotinylated anti-rat (CD31, Ki67,
CD41) or anti-rabbit (cleaved caspase-3) antibody for 30 minutes
diluted 1:300 in blocking buffer. After washing, sections were
incubated with HRP-conjugated streptavidin (SA-5004/Vector
Laboratories) diluted 1:200 in blocking buffer for 30 minutes at
room temperature. Binding sites were subsequently visualized with
a HRP substrate using the AEC Peroxidase Substrate Kit (SK-
4200/Vector Laboratories). Hematoxylin staining was used to
visualize nuclei.
Quantification of proliferation, apoptosis, vascularization
and platelets in tissue
The proportion of proliferative and apoptotic cells in tumors
was assessed by manual counting of the total number of cells and
the number of Ki67 and cleaved caspase-3 positive cells
respectively. A total number of 5000 cells were counted for Ki67
and approximately 30 000 cells were counted for cleaved caspase-
3 in each group, in tumor tissue derived from n=3 individuals/
group (cleaved caspase-3) or n=4 individuals /group (Ki67).
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quantified by stereology as previously described in tissue from
n=7 individuals/group [21].
Analysis of CD41 positive platelets in kidney from healthy mice
were done by manual counting of all positively stained platelets in
sections from whole kidney from n=5–6 individuals/group. The
data is given as average number of platelets/field. The proportion
of platelets in tumor tissue is much higher compared to healthy
tissue and the area stained positive for CD41 in tumors was
therefore quantified using the image analysis program Image J
1.42 software (National Institutes of Health). The data is presented
as % of total tumor area.
Blood sampling
Blood was drawn by cardiac puncture from isoflurane
anesthetized mice and anti-coagulated with 0,00129 M citrate.
Platelet aggregation
Citrated blood was centrifuged at 1800 rpm for 5 minutes and
the supernatant was further centrifuged at 800 rpm for 6 minutes
to obtain platelet-rich plasma (PRP). To obtain platelet-poor
plasma (PPP), the supernatant was additionally centrifuged at
3000 g for 10 minutes. Platelet count was adjusted to 350610
3
platelets/ml with PPP or Tyrode’s buffer. Aggregation was induced
with 20 mg/ml collagen, 0,15 U/ml bovine thrombin or 20 mM
ADP. Platelet aggregation activity was measured in a platelet
aggregometer (Labor FIBRINTIMERH, Ahrensburg, Germany)
where light transmission is recorded over time. Light transmission
is increased as platelets aggregate.
Platelet analysis in mouse blood with flow cytometry and
cell counting
For flow cytometry, 5 ml citrated blood was incubated with
antibody and HEPES-buffered saline (145 mM NaCl, 5 mM KCl,
1 mM MgSO4, 10 mM HEPES, pH 7,4) in a total volume of
50 ml. Dilution of antibodies were 1:10 for anti-fibrinogen, anti-
GPIIb/IIIa, anti-GPIX and anti-P-selectin. ADP activation was
done with 5–20 mM ADP for 15 minutes at room temperature and
stopped by addition of 400 ml 0,4% PFA/PBS (pH 7,4) and
incubation at room temperature for 15 minutes. Thrombin
activation was performed using 0,01 U/ml thrombin (HCT-
0020 Haematologic technologies inc), together with 1 mM
Pefabloc
FG (Pentapharm) to prevent fibrin clot formation.
Activation was ended at different time points by fixation of cells
with 400 ml 0,4% PFA/PBS (pH 7,4). Staining with antibodies
was done after fixation and washing of thrombin activated
samples. Samples were washed with 1 ml PBS and centrifuged
at 1500g for 15 minutes and cells resuspended in 0,5 ml PBS prior
to analysis. Flow cytometric analysis was performed and platelets
were gated to see mean fluorescence intensity (MFI) of the
respective antibody staining for the platelet population. For
platelet numbers, either whole blood was stained as described
above and GPIX positive cells given as percentage of the total
number of cells in whole blood, or the absolute number of
platelets/volume in whole blood was determined using a cell
counter (Coulter).
Blocking of platelet activation by Plavix
C57BL/6 female mice, wild type (Taconic, Denmark) and
HRG
2/2, were treated with Plavix (clopidogrel; Sanofi pharma)
at 0,25 mg/ml (30 mg/kg/day) or 0,50 mg/ml (60 mg/kg/day) in
their drinking water during three days. Control mice received only
water. Mice were anesthetized with isoflurane, blood drawn by
cardiac puncture and anti-coagulated with 0,00129 M citrate
before analysis of ADP-induced activation of the fibrinogen
receptor and the relative number of GPIX positive platelets in
whole blood.
GP1ba treatment of RT2/HRG
+/+ and RT2/HRG
2/2 mice
Angiogenic islets: GP1ba treatment of RT2/HRG
+/+ or RT2/
HRG
2/2 female mice started with 4 mg GP1ba antibody/g body
weight (60 mg/mouse) at five weeks of age (day 0), administered by
intra-peritoneal injection. The treatment was continued with 2 mg
GP1ba antibody/g body weight (30 mg/mouse) every third day
until day 9. The mice were then allowed to recover platelet levels
for five days prior pancreatic dissection and counting of angiogenic
islets at day 14, when the mice were seven weeks old.
Tumor volume: GP1ba treatment of RT2/HRG
+/+ or RT2/
HRG
2/2 female mice started at nine weeks of age (day 0) and
continued with injections every third day until day 12. The mice
were then allowed to recover platelet levels for nine days prior
pancreatic dissection and analysis of tumor volume at day 21,
when the mice were 12 weeks old.
Statistical analysis
All statistical analyses in this study were performed using the
non-parametric two-tailed Mann-Whitney test. The Mann-
Whitney test should be used instead of the parametric Student’s
t-test when the number of observations in each group are few
(approximately ,50). * is defined as p#0.05, ** as p#0.01 and
*** as p#0.001.
Results
Generation of HRG-deficient RIP1-Tag2 mice
With the aim to investigate how lack of HRG affects tumor
angiogenesis and growth in vivo, we crossed HRG-deficient mice
with the RIP1-Tag2 model of spontaneous insulinoma [19]. This
transgenic tumor model carries the SV40 T antigens under control
of the rat insulin promoter, which is expressed in the islets of
Langerhans in the pancreas. The RIP1-Tag2 mouse is an
orthotopic model of multistage carcinogenesis and is considered
to be a more accurate model for the stepwise development of
tumors than conventional subcutaneous models with injected
tumor cells. One of these stages represents the ‘‘angiogenic
switch’’, which is required for the transition from hyperplasia to
neoplasia and further tumor growth. During this stage, the islet
capillaries that are normally quiescent, are characterized by
endothelial proliferation, vascular dilation and microhemorrha-
ging. Around 10% of the 400 islets present in a mouse pancreas
adapt an angiogenic phenotype and out of these angiogenic islets
12–25% further develop into larger tumors [19].
RIP1-Tag2 positive (RT2) HRG heterozygote (HRG
+/2)m a l e s
were mated with RIP1-Tag2 negative HRG
+/2 females to enable
analysis of HRG wild type (HRG
+/+)and HRGknockout (HRG
2/2)
littermates in a RT2 positive genetic background. The genotypes of
the mice were determined by PCR (Fig. 1A). The following PCR-
products were generated; RT2 449 bp, HRG
+/+ 310 bp, HRG
2/2
378 bp and HRG
+/2 310 and 378 bp (Fig. 1B).
Accelerated tumor growth in HRG-deficient RIP1-Tag2
mice
Analysis of tumor growth in RT2/HRG
+/+ and RT2/HRG
2/2
mice was performed on gender-matched groups at two ages, 12 and
15 weeks. The total tumor burden was assessed by two parameters;
total tumor volume and number of tumors. At 12 weeks of age, the
mean total tumor volume in the HRG
2/2 group was two times
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+/+ group (Fig. 2A, table 1). Three weeks
later, at 15 weeks of age, the difference between the two groups was
furtherenhanced.Atthis time point the mean totaltumorvolumein
the HRG
2/2 group was more than three times higher than in the
HRG
+/+ group (Fig. 2B, table 1). The number of tumors did not
differ between the groups at any age (data not shown).
Tumors in HRG-deficient RIP1-Tag2 mice display
increased proliferation
To investigate why tumors were larger in HRG-deficient mice,
we analyzed the proliferative and apoptotic status, as well as the
vascularization, of the dissected tumors. Immunohistochemical
stainings directed against Ki67 revealed a significantly increased
proliferation in tumors from the RT2/HRG
2/2 group compared
to the RT2/HRG
+/+ group (Fig. 3A and C). No difference in
apoptosis was detected as judged from immunohistochemical
stainings directed against cleaved caspase-3 (data not shown).
We have in a previous study shown that lack of HRG affects the
angiogenic switch in the RIP1-Tag2 model with significantly
elevated numbers of angiogenic islets in RT2/HRG
2/2 mice as
compared with RT2/HRG
+/+ littermates at 7 weeks of age [3].
To investigate how lack of HRG affects pathological angiogenesis
in established tumors we performed stereological quantification
[21] of tumor vascularization in 12 weeks old RT2/HRG
+/+ and
RT2/HRG
2/2 mice. This method estimates the total length,
volume and surface area of the vasculature per tumor volume. In
contrast to our findings regarding the angiogenic switch, we could
not detect any statistically significant differences between RT2/
HRG
+/+ and RT2/HRG
2/2 mice with respect to vascularization
of established tumors (Fig. 3B, D–F).
Enhanced platelet aggregation in HRG-deficient mice
HRG
2/2 mice have a shorter bleeding time than wild type
mice [7], suggesting that platelet function may be regulated by
HRG. To address this possibility we analyzed whether activation
of platelets was affected in HRG-deficient mice. Platelet activation
can be measured by their extent of aggregation following
activation in vitro. For this purpose an aggregometer was used
and light transmission recorded over time. As platelets aggregate,
light transmission is increased. Platelet-rich plasma (PRP) was
prepared from RT2-negative HRG
+/+ and HRG
2/2 mice and
platelets were activated by the addition of collagen (20 mg/ml),
thrombin (0,15 U/ml) or ADP (20 mM). All three platelet
activators enhanced aggregation in HRG
2/2 PRP compared to
Figure 1. Genotyping PCR. Offspring from mating between RT2/HRG
+/2 males and HRG
+/2 females were genotyped by a five-primer PCR. (A) The
five primers give three distinct PCR products. Primer pair F-127/R+183 gives a 310 bp HRG wild type allele product, primer pair F-127/RNeo gives a
378 bp HRG knockout allele product and primer pair RT1/RT2 gives a 449 bp RT2 transgene allele product. The location of each primer is indicated in
the map by an arrow. (B) PCR products separated on a 2% agarose gel. All six possible genotypes are presented.
doi:10.1371/journal.pone.0014526.g001
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+/+ PRP (Fig. 4A). The HRG deficient mice used for this
assay were either on a pure C57BL/6 (B6) or a mixed 129/
Ola,C57BL/6 (129/B6) genetic background.
To determine if this fast aggregation was accompanied by an
increased expression of platelet surface activation markers, we
activated platelets from HRG
+/+ and HRG
2/2 mice with
thrombin or ADP and analyzed expression of P-selectin and the
activated fibrinogen receptor (GPIIb/IIIa) by flow cytometry in
whole blood. No difference in the upregulation of these activation
markers could be detected between platelets from wild type and
HRG-deficient mice (Fig. 4B and C). These data indicate that the
enhanced platelet aggregation in mice lacking HRG is most likely
caused by an alteration in the plasma milieu surrounding the
platelets, rather than related to the activation status of the platelets
per se.
The level of circulating platelets is regulated by HRG
To further analyze platelet activation in vivo in HRG knockout
mice, we measured the level of circulating platelets as well as the
presence of platelets in tissue from HRG
+/+ and HRG
2/2 mice.
Activated platelets leave the circulation and become arrested in the
vascular bed. A reduced number of platelets in the blood can
therefore reflect an increase in platelet activation. We analyzed the
number of circulating platelets in whole blood from healthy (RT2-
negative) wild type and HRG-deficient mice using a cell counter.
There was a significant decrease in the number of platelets in
blood from HRG
2/2 mice compared to wild type (Fig. 5A),
supporting the conclusion that platelets are more easily activated
in the absence of HRG. It is well established that tumors can
promote coagulation and platelet activation, for instance by
expression of tissue factor [22]. In agreement, platelet levels were
significantly reduced in blood from wild type mice with insulinoma
(RT2/HRG
+/+) compared to healthy wild types (HRG
+/+)
(Fig. 5A). However, RT2-positive HRG
2/2 mice (RT2/HRG
2/2)
showed no further decrease in platelet numbers compared to
HRG
2/2 mice without tumors (HRG
2/2). Healthy HRG-deficient
mice had in fact similar platelet levels as wild type mice with
insulinoma (Fig. 5A).
To determine the amount of platelets arrested in tissue in
healthy (RT2-negative) mice, immunohistochemical analysis of
kidney from wild type and HRG knockout mice was performed
using an antibody against the platelet marker CD41. As can be
seen in figure 5B (left panel) and C, a significantly higher number
of platelets was detected in tissue from mice lacking HRG. When
the same analysis was performed on tumor tissue, as well as kidney
(data not shown), from RT2-positive HRG
+/+ and HRG
2/2 mice,
no statistically significant difference with respect to CD41 staining
could be detected between the two groups of mice (Fig. 5B (right
panel) and D). This result is in agreement with the similar levels of
circulating platelets in RT2-positive (HRG
+/+ and HRG
2/2)
mice, regardless of genotype (Fig. 5A), and probably reflects the
platelet activating properties of tumor cells.
To directly address if enhanced platelet activation caused the
reduction in circulating platelets in mice lacking HRG, we
employed the drug Plavix (clopidogrel), which inhibits platelet
activation via the ADP receptor P2Y. Two doses of the inhibitor
were administered via the drinking water; 30 mg/kg/day
(=0,25 mg/ml) or 60 mg/kg/day (=0,50 mg/ml) during three
days. To assess the efficacy of the treatment, blood was drawn by
cardiac puncture and activation of the fibrinogen receptor
(GPIIb/IIIa) was analyzed by flow cytometry after ADP activation
in vitro. Both doses blocked platelet activation by ADP, in wild type
as well as in HRG-deficient mice (Fig. 5E). We next analyzed
whether treatment with Plavix could affect platelet levels in the
circulation of wild type and HRG-deficient mice. Platelet levels
were measured by flow cytometric analysis of mouse whole blood
using a FITC-conjugated GPIX antibody. HRG-deficient mice
treated with 25 and 50 mg/ml Plavix showed a dose-dependent
increase in platelet levels in the circulation compared to untreated
mice (Fig. 5F). In contrast, Plavix induced no change in platelet
levels in wild type mice. These data support the conclusion that
Figure 2. Tumor volume is increased in RT2/HRG
2/2 compared to RT2/HRG
+/+ mice. Tumors were dissected and measured. Tumor volumes
were calculated by the formula ((p/6)6width
26length). Each dot represents the summarized tumor volume in mm
3 from one mouse at (A) 12 weeks
of age (n
+/+=16; n
2/2=16) and at (B) 15 weeks of age (n
+/+=11; n
2/2=12). Statistical analyses were performed with a two-tailed Mann-Whitney test,
vertical bars represent standard deviation, * p#0.05.
doi:10.1371/journal.pone.0014526.g002
Table 1. Mean tumor volume in RT2/HRG
+/+ and RT2/HRG
2/2
mice at 12 and 15 weeks.
Mean total tumor volume ± SD (mm
3)
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mice lacking HRG.
Platelet depletion attenuates the pro-angiogenic
phenotype of HRG-deficient RIP1-Tag2 mice
Lack of HRG enhances the angiogenic switch [3] and, as
demonstrated here, growth of insulinoma in the RIP1-Tag2
mouse. The angiogenic switch is a prerequisite for the transition of
hyperplastic tissue into a growing tumor. To find out whether
there is a connection between the enhanced angiogenic switch and
the increased platelet activation in HRG-deficient mice, we
depleted RT2/HRG
+/+ and RT2/HRG
2/2 mice of platelets
using an antibody binding to the platelet adhesion molecule
GP1ba. The mice were treated during two weeks prior to analysis
of angiogenic islets at the age of seven weeks. Platelet depletion
significantly reduced the number of angiogenic islets in the RT2/
HRG
2/2 group, but did not affect the number of angiogenic islets
in RT2/HRG
+/+ mice (Fig. 6). When administration of the anti-
GP1ba antibody was initiated at a later stage (age nine weeks),
after the onset of the angiogenic switch, platelet depletion did not
suppress tumor growth in HRG-deficient mice (Fig. 6).
In conclusion, our data suggests that increased platelet
activation is the primary cause of the elevated angiogenic switch
in HRG-deficient RIP1-Tag2 mice.
Discussion
In the present study we describe three main findings; 1) tumor
growth is significantly increased in HRG-deficient mice, 2) platelet
activation is enhanced in mice lacking HRG and 3) the increased
platelet activation mediates the accelerated angiogenic switch seen
in HRG-deficient mice. These findings are discussed below.
The transgenic RIP1-Tag2 mouse is an orthotopic model of
multistage carcinogenesis and believed to better reflect the
stepwise process of tumor development via distinctive stages, than
conventional subcutaneous models with injected tumor cells
[19,23]. The RIP1-Tag2 mouse is well suited for studies of
angiogenesis, since one of the stages during tumor progression is
Figure 3. Proliferation and vascularization in tumors from RT2/HRG
+/+ and RT2/HRG
2/2 mice. (A, B) Immunohistochemical staining of
tumor tissue from HRG
+/+ and HRG
2/2 mice directed against Ki67 (A) and CD31 (B). (C) Quantification of immunohistochemical staining directed
against Ki67 was performed on tumor sections from RT2/HRG
+/+ and RT2/HRG
2/2 mice. Data are presented as percentage of Ki67 positive cells of
total cell numbers. Each dot represents the value from an individual animal (n=4 for each group). (D–F) Stereological quantification of vascular
parameters: length, volumetric and surface densities. Each dot represents the mean value from one individual animal (n=7 for each group). Statistical
analyses were performed with a two-tailed Mann-Whitney test, vertical bars represent standard deviation, * p#0.05. Scale bars represent 50 mmi nA
and 100 mmi nB .
doi:10.1371/journal.pone.0014526.g003
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We have recently reported that the angiogenic switch is
significantly elevated in HRG
2/2 mice with an approximately
two times increase in the number of angiogenic islets [3]. In the
present study, HRG
2/2 mice were found to have a larger tumor
volume compared to their HRG
+/+ littermates. We also noted that
HRG
+/2 mice have an intermediary tumor volume (data not
shown) between HRG
+/+ and HRG
2/2 mice, which may be re-
lated to the fact that mice with one inactivated HRG allele have
approximately half the serum concentration of HRG-protein com-
pared to HRG sufficient mice [7]. At 12 weeks of age, HRG
2/2
mice have an approximately two times larger tumor volume than
HRG
+/+ mice. The correlation - with the same increase in number
of angiogenic islets as the increase in tumor volume at 12 weeks –
probably reflects that the islets that have undergone the angiogenic
switch receive a headstart in the carcinoma development. The
reason why we do not see an increased number of tumors is likely
because growing islets and/or tumors fuse and become larger
tumors. The difference in tumor volume between HRG
+/+ and
HRG
2/2 mice was enhanced over time with a three times
increase in total tumor burden at week 15. This finding is in
agreement with the increased proliferation detected in tumor tissue
from mice lacking HRG. These data support a role of HRG as an
endogenous regulator of tumor growth.
We did not detect any significant difference between HRG
+/+
and HRG
2/2 mice with respect to vascularization of established
tumors. The reason for this finding is not known but might relate
to the particular tumor that is being studied. Established Rip1-
Tag2 tumors are highly vascularised in wild type mice and lack of
HRG may not be able to promote this further. In contrast, lack of
HRG significantly enhances the early onset of pathological
angiogenesis in this model [3].
HRG-deficient mice are viable and fertile, but have a
coagulation defect resulting in shorter bleeding times [7]. This is
an expected phenotype, since HRG has been implicated in
regulation of the coagulation system in a number of previous
Figure 4. Enhanced aggregation of platelets in HRG
2/2 mice. (A) Collagen, thrombin and ADP-induced platelet aggregation in PRP from
HRG
+/+ and HRG
2/2 mice on a pure C57BL/6 (B6) or on a mixed 129/Ola, C57BL/6 (129/B6) genetic background was measured with an aggregometry
assay. Aggregation levels are represented by light transmission through PRP over time. (B–C) Flow cytometric analyses of thrombin- and ADP-
induced activation of platelets presented by mean fluorescent intensity (MFI). Ligands were added at time=0. Each symbol (squares=HRG
+/+, open
triangles=HRG
2/2) represents the mean value from three independent measurements. Vertical bars represent standard deviation. (B) P-selectin after
activation with 0,01 U/ml thrombin measured at 0, 1, 3, 5 and 10 minutes. (C) Activated fibrinogen receptor (GPIIb/IIIa) after 15 minutes stimulation
with 1 or 10 mM ADP.
doi:10.1371/journal.pone.0014526.g004
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molecules regulating both angiogenesis and hemostasis. The
reason for this dual function is unclear, but may reflect an
inherent requirement for strict regulation of the angiogenic process
during hemostasis. Angiogenesis must be counteracted at the early
stages of vascular injury and platelet adhesion. At a later stage,
when the clot has stabilized, angiogenesis is required for tissue
regeneration and a new vessel wall is formed from activated
endothelial cells. The different steps in this process need to be
carefully orchestrated to prevent hemorrhage [8,13].
Motivated by the reported coagulation defect in HRG-deficient
mice, we investigated their platelet activation status and found a
significantly faster in vitro-aggregation in PRP from HRG-deficient
mice compared to wild type using three established platelet-
activators: collagen, thrombin and ADP. Furthermore, the level of
circulating platelets was decreased in mice lacking HRG, a likely
consequence of activation-induced tissue arrest. The reason
behind the increased platelet activation in mice that lack HRG
is not known, but currently under investigation. Our data indicate
that the enhanced platelet aggregation is induced by a factor
outside the platelets, since their expression levels of activation
markers such as the fibrinogen receptor GPIIb/IIIa and P-selectin
were similar in wild type and HRG-deficient mice. It has been
reported that the interaction of HRG with fibrinogen delays the
conversion to fibrin [25], which could be one explanation for the
faster platelet aggregation in HRG
2/2 mice. However, we
Figure 5. HRG regulates platelet levels in the circulation. (A) Platelet numbers in whole blood from RT2 positive or negative mice with
different HRG genotypes (HRG
+/+ or HRG
2/2). (B) Left panel; Quantification of the number of platelets/field in kidney tissue from healthy (RT2-
negative) HRG
+/+ or HRG
2/2 mice. Right panel; Quantification of the area percentage stained positive for the platelet marker CD41 in tumor tissue
from RT2-positive HRG
+/+ and HRG
2/2 mice. (C, D) Immunohistochemical staining directed against CD41 was performed on kidney from RT2-negative
mice (C) and tumor tissue from RT2-positive mice (D) from both genotypes. Arrows indicate platelets. (E) HRG
+/+ and HRG
2/2 mice were treated with
Plavix (25 mg/ml or 50 mg/ml in drinking water) for three days. Platelet activation in whole blood was measured after stimulation with 10 mM ADP by
flow cytometric analysis of the activated fibrinogen receptor (GPIIb/IIIa). (D) Platelet levels after Plavix treatment were measured by flow cytometric
analysis in whole blood and are presented as the percentage of GPIX positive cells. Statistical analyses were performed with a two-tailed Mann-
Whitney test, vertical bars represent standard deviation, * p#0.05, ns=non significant. Scale bars represent 50 mm in C and 100 mmi nD .
doi:10.1371/journal.pone.0014526.g005
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after stimulation with ADP, which most likely does not involve
fibrinogen conversion to fibrin.
Platelets have in several different experimental settings been
shown to stimulate angiogenesis [11,14,15,16,17], even though
they contain both positive and negative regulators of blood vessel
formation [16,26]. Since HRG-deficient mice display an enhanced
coagulation and increased platelet activation, we hypothesized that
there could be a connection between this phenotype and our
previous finding of an elevated angiogenic switch in these mice [3].
To test this hypothesis we rendered the mice thrombocytopenic by
intraperitoneal injections of a GP1ba antibody. This treatment
suppressed the increase in number of angiogenic islets in HRG-
deficient RIP1-Tag2 mice to wild type level, showing that an
enhanced activation of platelets mediates the increased angiogenic
switch in these mice. Interestingly, when administration of the
anti-GP1ba antibody was initiated after the onset of the
angiogenic switch, platelet depletion did not suppress tumor
growth in HRG-deficient mice. We therefore conclude that
platelets play a crucial role in the early stages of tumor
development but are of less significance once angiogenesis has
been initiated.
The mechanism behind this contribution of activated platelets to
the angiogenic switch is not clear but could involve secretion of
proangiogenic factors that stimulate angiogenesis. In addition,
platelets contain a number of proteases that upon activation and
degranulation of the platelets can increase the bioavailability of
matrix-bound growth factors, such as VEGF. Moreover, a fibrin
clot may provide a favourable matrix supporting angiogenesis.
Another possibility is that other types of blood cells, such as
monocytes/macrophages or neutrophils, form complexes with the
activated platelets, thereby facilitating their entry into the tumor
stroma. Monocytes/macrophages and neutrophils have in several
studies been demonstrated to have the capacity to stimulate tumor
vascularization and growth [27,28]. However, preliminary data
from our lab indicate that there areno differencesbetween HRG
+/+
and HRG
2/2 mice with respect to the number of infiltrating
inflammatory cells into the tumor tissue. There could however still
be functional differences between these cells in the two genotypes.
We have recently shown that a proteolytic fragment of HRG,
corresponding to the antiangiogenic domain, is present in human
tissue. In addition, we show that this HRG-fragment can bind to
endothelium in the presence of activated platelets and hence exert
its antiangiogenic effect [3]. This means that the enhanced
angiogenic switch in HRG-deficient mice may have two
components; 1) increased platelet activation, due to lack of
HRG, that stimulates angiogenesis by the mechanisms mentioned
above and 2) the antiangiogenic HRG-fragment that counteracts
angiogenesis in the presence of activated platelets is missing. The
part of HRG that regulates platelet aggregation may be distinct
from the antiangiogenic fragment, which is derived from the His/
Pro-rich domain.
In summary, this study shows for the first time that tumor
growth is enhanced in mice that lack HRG. Moreover, we show
that HRG-deficient mice have increased platelet activation.
Finally, we demonstrate that the elevated platelet activation in
HRG-deficient mice accelerates the angiogenic switch in the
RIP1-Tag2 tumor model. These data further establish platelets as
regulators of angiogenesis, especially in a pathological setting.
Moreover, we can firmly establish a role for HRG as a modulator
of both hemostasis and pathological angiogenesis.
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group) were rendered thrombocytopenic by treatment with an anti-GP1ba antibody during two weeks before the onset of the angiogenic switch. At
7 weeks of age angiogenic islets were counted in each animal. A second group of RT2/HRG
2/2 mice were treated with the anti-GP1ba antibody
during two weeks after the angiogenic switch and tumor volumes analyzed at 12 weeks of age (n=6/group). (Data on untreated animals at 7 weeks
were originally published in [3].) Statistical analyses were performed with a two-tailed Mann-Whitney test, vertical bars represent standard deviation,
** p#0.001, ns=non significant.
doi:10.1371/journal.pone.0014526.g006
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